

Attorney Docket No: 23546-07724US

Client Ref: RTS-0333

USSN: 10/008,789

AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound 8 to 50 nucleobases in length targeted to ~~nucleobases 259 through 1586 of the coding region of the 5' untranslated region, the start codon region, the coding region, the stop codon region, or the 3' untranslated region~~ of a nucleic acid molecule of SEQ ID NO:3 encoding thyroid hormone receptor interactor 6, ~~with the proviso of not including nucleobases 1608 through 1642 of SEQ ID NO:3~~, wherein said compound specifically hybridizes with ~~one of said regions~~ and inhibits the expression of thyroid hormone receptor interactor 6.

2. (original) The compound of claim 1 which is an antisense oligonucleotide.

3. (canceled)

4. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (original): The compound of claim 4, wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (original): The compound of claim 6, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (original): The compound of claim 8, wherein the modified nucleobase is a 5-methylcytosine.

10. (original): The compound of claim 2, wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (canceled)

12. (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Attorney Docket No: 23546-07724US
Client Ref: RTS-0333
USSN: 10/008,789

13. (original): The composition of claim 12 further comprising a colloidal dispersion system.

14. (original): The composition of claim 12, wherein the compound is an antisense oligonucleotide.

15. (previously presented): A method of inhibiting the expression of thyroid hormone receptor interactor 6 in cells or tissues comprising contacting said cells or tissues *in vitro* with the antisense compound of claim 1 so that expression of thyroid hormone receptor interactor 6 is inhibited.

16-18. (canceled)

19. (currently amended): The compound of claim 1 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound specifically hybridizes with and differentially inhibits by at least 41% the expression of a first variant of thyroid hormone receptor interactor 6, TRIP6-I (SEQ ID NO:3) relative to a second variant of thyroid hormone receptor interactor 6, TRIP6-II (SEQ ID NO:11). ~~one or more of the variants of thyroid hormone receptor interactor 6 relative to the remaining variants of thyroid hormone receptor interactor 6.~~

20. (previously presented): The compound of claim 19 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound hybridizes with and specifically inhibits the expression of TRIP6-I (SEQ ID NO:3).

21. (withdrawn): The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 13, 14, 16, 17, 18, 19, 22, 23, 25, 26, 27, 29, 30, 31, 33, 35, 40, 41, 43, 45, 46, 47, 48, 49, 51, 53, 54, 55, 56, 57, 59, 60, 61, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 76, 78, 81, 84, 87 or 88.

22. (withdrawn): The compound of claim 21, wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:22.